Skip to content
Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
The American Society of Oncology (ASCO) 2018 Annual Meeting was held in Chicago, IL, from 1–5 June 2018. ASCO 2018 brought together key oncology professionals from around the world, who presented cutting-edge updates from hot topics across oncology disciplines.
Highlights in hematological oncology from this year’s meeting included perspectives on MRD in the clinical setting, updates from exciting clinical trials including ARROW and OPTIMISMM, and the latest data on CAR T-cells.
CAR T-cells
One of the most highly anticipated areas of research at ASCO 2018, CAR T-cells represent an exciting treatment option across a range of hematological malignancies.
Find out about the latest CAR T-cell therapies, toxicity and management data, role in transplant, and the future of the field.
View more
Measurable Residual Disease
MRD is gaining traction as both a prognostic indicator and a biomarker for treatment strategizing.
A key field of interest in hemonc, MRD was much-discussed at ASCO 2018. Topics included using MRD in the clinical setting, relevance in transplant, and use of MRD as a clinical trial endpoint.
View more